PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 1, 2003American Journal of Clinical Pathology190 citations

Quantitative Analysis of Serum Free Light Chains

View Full Paper
RARoshini S. AbrahamJKJerry A. KatzmannRCRaynell Clark

Key Points

  • To evaluate the clinical utility of a quantitative nephelometric serum free light chain (FLC) assay for detecting monoclonal FLCs and monitoring patients with primary systemic amyloidosis.
  • Retrospective evaluation of quantitative serum nephelometric FLC measurements in N=95 patients with primary systemic amyloidosis.
  • Comparison of nephelometric assay sensitivity against conventional serum and urine immunofixation electrophoresis.
  • Assessment of serial FLC quantification for disease monitoring in patients undergoing stem cell transplantation.
  • Nephelometric quantification of serum FLCs identified abnormal monoclonal light chains in patients who had negative immunofixation results in serum, urine, or both.
  • Quantitative serum FLC measurements provided an effective surveillance tool for tracking treatment response and disease course following stem cell transplantation.

Abstract

Primary systemic amyloidosis is a plasma cell dyscrasia characterized by the accumulation of excess free immunoglobulin light chains (FLCs) as amyloid. One of the diagnostic features of amyloidosis is the presence of circulating monoclonal FLCs in the serum and urine of the patients. The FLC usually is present in small amounts, and immunofixation is required for detection. A nephelometric method for quantitating FLCs in serum has been described using antibodies that recognize only FLC not bound to heavy chain. We describe a retrospective study using this quantitative FLC method for assessing monoclonal FLCs in 95 patients with amyloidosis. The sensitivity of nephelometric serum FLC measurements is particularly useful in patients with negative immunofixation results for serum, urine, or both. In addition, the FLC assay can be used for follow-up of patients with amyloidosis who have undergone stem cell transplantation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Abraham et al. (2003) studied this question.

synapsesocial.com/papers/6a12ec5ffb24b1a422a5fd47https://doi.org/10.1309/lywm47k2l8xyffb3
Ask AI
Helpful
Bookmark
Share
View Full Paper